Immix Biopharma’s (IMMX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Immix Biopharma (NASDAQ:IMMX) in a report published on Monday morning,Benzinga reports. The brokerage currently has a $7.00 target price on the stock.

Immix Biopharma Stock Performance

Immix Biopharma stock opened at $1.97 on Monday. Immix Biopharma has a one year low of $1.26 and a one year high of $3.80. The stock has a fifty day moving average of $2.14 and a 200 day moving average of $1.93. The stock has a market cap of $54.19 million, a PE ratio of -2.32 and a beta of 0.24.

Immix Biopharma (NASDAQ:IMMX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.08). As a group, sell-side analysts predict that Immix Biopharma will post -0.87 EPS for the current fiscal year.

Institutional Trading of Immix Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of IMMX. Geode Capital Management LLC increased its holdings in Immix Biopharma by 5.6% in the 3rd quarter. Geode Capital Management LLC now owns 150,082 shares of the company’s stock worth $224,000 after acquiring an additional 7,954 shares in the last quarter. SBI Securities Co. Ltd. bought a new position in Immix Biopharma in the 4th quarter worth $38,000. Finally, FNY Investment Advisers LLC purchased a new stake in Immix Biopharma in the 4th quarter worth $63,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.